Atezolizumab and bevacizumab for non‐resectable or metastatic combined hepatocellular‐cholangiocarcinoma: A multicentric retrospective study

Abstract

BackgroundsThe efficacy of atezolizumab/bevacizumab has never been reported in patients with metastatic/unresectable combined hepatocellular‐cholangiocarcinoma (cHCC‐CCA).Patients and MethodsWe retrospectively included patients with a histological diagnosis of unresectable/metastatic cHCC‐CCA and treated with atezolizumab/bevacizumab (2020–2022) in 7 centers. Clinical and radiological features were collected at the beginning of atezolizumab/bevacizumab. We reported the radiological response using RECIST criteria, overall survival (OS) and progression‐free survival (PFS).ResultsSixteen patients with cHCC‐CCA were included and were predominantly male (75%) with advanced fibrosis/cirrhosis (69%). Nine patients received atezolizumab/bevacizumab as a first‐line systemic treatment, 5 as a second line, 1 as a third line and 1 as a fifth line. Severe digestive bleeding occurred in 2 patients. Among the 9 patients treated in the first line, 4 experienced radiological progression, 3 partial response and 1 had stable disease. Patients treated with atezolizumab/bevacizumab in the first line had a median OS of 13 months and a median PFS of 3 months. Among the 7 patients receiving atezolizumab/bevacizumab as a second line or more, 4 patients harbored a stable disease, 2 a partial response, and 1 a progressive disease.ConclusionsThe combination of atezolizumab and bevacizumab showed signs of anti‐tumor efficacy in patients with unresectable/metastatic cHCC‐CCA.

Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study

“…In the setting of targeted immunotherapy, bevacizumab combined with a PD-1/PD-L1 inhibitor have achieved encouraging results in HCC patients ( 31 ). Notably, bevacizumab combined with a PD-1/PD-L1 inhibitor has achieved anti-tumor efficacy in hepatocellular-cholangiocarcinoma ( 32 ), which implies effectiveness against BTC. Case reports have shown their potential value for GBC treatment ( 18 , 33 ).…”